JP2018519359A - Ｐｅｇ化顆粒球コロニー刺激因子（ｇｃｓｆ） - Google Patents

Ｐｅｇ化顆粒球コロニー刺激因子（ｇｃｓｆ） Download PDF

Info

Publication number
JP2018519359A
JP2018519359A JP2018516407A JP2018516407A JP2018519359A JP 2018519359 A JP2018519359 A JP 2018519359A JP 2018516407 A JP2018516407 A JP 2018516407A JP 2018516407 A JP2018516407 A JP 2018516407A JP 2018519359 A JP2018519359 A JP 2018519359A
Authority
JP
Japan
Prior art keywords
gcsf
peg
pegx
histidine residue
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018516407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519359A5 (enExample
Inventor
アブラハム アブホフスキ、
アブラハム アブホフスキ、
ロナルド ジー． ジュビン、
ロナルド ジー． ジュビン、
ピーター ジェイ． ブオンテンポ、
ピーター ジェイ． ブオンテンポ、
フリーデリケ カゾ、
フリーデリケ カゾ、
Original Assignee
アンビオ ファーマシューティカルズ，エルエルシー
アンビオ ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンビオ ファーマシューティカルズ，エルエルシー, アンビオ ファーマシューティカルズ，エルエルシー filed Critical アンビオ ファーマシューティカルズ，エルエルシー
Publication of JP2018519359A publication Critical patent/JP2018519359A/ja
Publication of JP2018519359A5 publication Critical patent/JP2018519359A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018516407A 2015-06-11 2016-06-13 Ｐｅｇ化顆粒球コロニー刺激因子（ｇｃｓｆ） Pending JP2018519359A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562174373P 2015-06-11 2015-06-11
US62/174,373 2015-06-11
US201562184042P 2015-06-24 2015-06-24
US62/184,042 2015-06-24
PCT/US2016/037278 WO2016201448A2 (en) 2015-06-11 2016-06-13 Pegylated granulocyte colony stimulating factor (gcsf)

Publications (2)

Publication Number Publication Date
JP2018519359A true JP2018519359A (ja) 2018-07-19
JP2018519359A5 JP2018519359A5 (enExample) 2019-07-18

Family

ID=57504855

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018516407A Pending JP2018519359A (ja) 2015-06-11 2016-06-13 Ｐｅｇ化顆粒球コロニー刺激因子（ｇｃｓｆ）

Country Status (11)

Country Link
US (1) US20160361426A1 (enExample)
EP (1) EP3307757A4 (enExample)
JP (1) JP2018519359A (enExample)
KR (1) KR20180017104A (enExample)
CN (1) CN107949565A (enExample)
AU (1) AU2016277147A1 (enExample)
CA (1) CA2988988A1 (enExample)
IL (1) IL256167A (enExample)
MX (1) MX2017016103A (enExample)
RU (1) RU2018100425A (enExample)
WO (1) WO2016201448A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022011630A (es) * 2020-03-20 2022-12-02 Amgen Inc Determinación del extremo n libre del pegfilgrastim utilizando una proteasa ácida.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506317A (ja) * 2001-07-11 2005-03-03 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｆｓ結合体
JP2009503111A (ja) * 2005-08-04 2009-01-29 ネクター セラピューティックス エイエル，コーポレイション Ｇ−ｃｓｆ部分および重合体の複合体
WO2011041376A1 (en) * 2009-09-30 2011-04-07 Prolong Pharmaceuticals Modified granulocyte colony stimulating factor (g-csf)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
AU1676992A (en) * 1991-03-18 1992-10-21 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US7144978B2 (en) * 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
ES2536710T3 (es) * 2002-03-25 2015-05-27 Arimed Inc. Nuevo uso terapéutico de LPC, ligandos agonistas específicos para el receptor G2A
US7892745B2 (en) * 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
AU2004296855B2 (en) * 2003-12-03 2011-01-06 Ratiopharm Gmbh Glycopegylated Granulocyte Colony Stimulating Factor
CA2607844C (en) * 2005-06-01 2012-07-10 Maxygen Holdings Ltd. Pegylated g-csf polypeptides and methods of producing same
CU23556A1 (es) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
US20110104100A1 (en) * 2007-10-04 2011-05-05 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
CN101602801A (zh) * 2008-06-13 2009-12-16 杭州九源基因工程有限公司 聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体
WO2011075606A2 (en) * 2009-12-18 2011-06-23 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
CN104109235B (zh) * 2014-05-30 2017-07-18 厦门赛诺邦格生物科技股份有限公司 一种具有氮原子支化中心的单一官能化聚乙二醇、制备方法及其生物相关物质

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506317A (ja) * 2001-07-11 2005-03-03 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｆｓ結合体
JP2009503111A (ja) * 2005-08-04 2009-01-29 ネクター セラピューティックス エイエル，コーポレイション Ｇ−ｃｓｆ部分および重合体の複合体
WO2011041376A1 (en) * 2009-09-30 2011-04-07 Prolong Pharmaceuticals Modified granulocyte colony stimulating factor (g-csf)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOTECHNOLOGY TECHNIQUES, vol. 12, no. 10, JPN6020024776, 1998, pages 751 - 754, ISSN: 0004517468 *

Also Published As

Publication number Publication date
EP3307757A4 (en) 2019-03-13
CA2988988A1 (en) 2016-12-15
WO2016201448A3 (en) 2017-02-09
AU2016277147A1 (en) 2018-01-18
US20160361426A1 (en) 2016-12-15
EP3307757A2 (en) 2018-04-18
IL256167A (en) 2018-04-30
RU2018100425A3 (enExample) 2019-11-21
CN107949565A (zh) 2018-04-20
KR20180017104A (ko) 2018-02-20
RU2018100425A (ru) 2019-07-15
WO2016201448A2 (en) 2016-12-15
MX2017016103A (es) 2018-05-22

Similar Documents

Publication Publication Date Title
JP5336372B2 (ja) Ｇ−ｃｓｆ部位特異的モノコンジュゲート
TWI364295B (en) Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
JP5539607B2 (ja) ポリマー−ｖｉｉｉ因子部分結合体
AU2016228555B2 (en) Conjugates of an IL-7 moiety and a polymer
US12036283B2 (en) Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
ZA200105932B (en) GCSF conjugates.
KR20070030308A (ko) 중합체­인자 ｉｘ 부분의 접합체
JP2009503111A (ja) Ｇ−ｃｓｆ部分および重合体の複合体
KR20100082774A (ko) 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ｂ, 이의 제조 방법 및 용도
JP2007533665A (ja) 新規ｇ−ｃｓｆ結合体
KR101330338B1 (ko) Ｇｍ―ｃｓｆ 부분 및 중합체의 콘쥬게이트
JP2019535700A (ja) ペグ化エンドスタチン類似体およびその適用
KR20100063108A (ko) 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
JP2018519359A (ja) Ｐｅｇ化顆粒球コロニー刺激因子（ｇｃｓｆ）
WO2011041376A1 (en) Modified granulocyte colony stimulating factor (g-csf)
KR102580477B1 (ko) 옥심-함유 결합을 갖는 인자 viii 모이어티의 컨쥬게이트
WO2001076639A2 (en) Chemically-modified myelopoietin conjugates
CZ20033537A3 (cs) Chemicky modifikované konjugáty progenipoietinu
EA043667B1 (ru) Длительно действующие агонисты рецептора интерлейкина-15, связанные с ними композиции и способы их получения и применения
HK1190736B (en) Mono- and di-peg il-10 production and uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220111